Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.
Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.